P/B
6,3
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
$114M
Market Cap • 9/18/2026
2003
(23 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
Canada
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,2
EPS
—
Market Cap
Market Cap
114M
EV
85,2M
EV/Revenue
0
EV/EBITDA
-1,1
EV/EBIT
-1,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-99,9%
Total Yield
-99,9%
Payout
0%
Retained Earnings
-485,3M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
207%
Capex/OCF
-0,6%
SBC/OCF
—
% PPE
0,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
19,1%
CAGR Net Income 5Y
21%
CAGR EPS 5Y
-5,7%
CAGR OCF 5Y
17,3%
Leverage
N.D./EBITDA
0,4
Debt/Equity
0%
Current Ratio
8,1
Quick Ratio
7,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!